T3	Effect 0 22	Grade 3 hepatotoxicity
T6	Subject 108 127	1.4% of MS patients
T7	Treatment 131 139	IFN beta
T5	Population 108 112	1.4%
T9	Drug 131 139	IFN beta
T10	Treat-Disorder 116 118	MS
T4	Adverse_event 85 93	observed
E1	Adverse_event:T4